STAT+: Eli Lilly’s stock falls after 2024 guidance misses forecasts
STAT
JANUARY 14, 2025
The company also expects revenue from all of 2024 to be $45 billion, lower than the range of $45.4 Lilly said the GLP-1 drugs Mounjaro and Zepbound are expected to have brought in $3.5 billion and $1.9 billion, respectively, in the fourth quarter. billion to $46 billion that it had previously guided.
Let's personalize your content